CAMBRIDGE - Biogen Idec Inc.'s first-quarter profit rose 50 percent, boosted by higher sales of the multiple sclerosis drug Avonex. (Full article: 297 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
